![]() |
|
|
Vol. 282, Issue 1, 420-429, 1997
Sleep Research Center, An endogenous neuroactive steroid, pregnanolone, and an orally
available synthetic analog, CCD-3693, were administered to rats at the
middle of their circadian activity phase (6 hr after lights off).
Electroencephalogram-defined sleep-wake states, locomotor activity and
body temperature were concurrently measured 30 hr before and after
treatment. Identical procedures were used to test triazolam and
zolpidem. Triazolam (0.1-1.6 mg/kg), zolpidem (2.5-10 mg/kg) and the
neuroactive steroids (10-30 mg/kg) produced dose-dependent increases
in non-rapid eye movement (NREM) sleep. At this dose and time of day
(in which the rats were predominantly awake during the 6 hr before
treatment) the neuroactive steroids appeared more intrinsically
efficacious in promoting NREM sleep than the benzodiazepine ligands.
The neurosteroids did not, however, significantly interfere with rapid
eye movement sleep and were more selective in reducing (EEG)
wakefulness, with relatively less locomotor activity impairment during
waking than triazolam and zolpidem. In addition, the benzodiazepine
receptor ligands showed distinct "rebound" wakefulness after the
NREM sleep-promoting effect subsided, although the neuroactive steroids
did not. In addition, in vitro binding studies and in
vivo pharmacological data confirmed that CCD-3693 was orally
active in standard tests of anxiety, anticonvulsant, loss-of-righting
and passive avoidance.
Copyright © by The American Society for Pharmacology and Experimental Therapeutics